Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

467
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
467
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

15
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
15
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

786
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
786
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

699
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
699
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

17
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
17
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

12
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
12

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A reporting checklist for large language models in behavioural science.

Nature human behaviour·2026
Same author

Training-oriented framework for brachytherapy treatment planning in soft tissue sarcoma.

Brachytherapy·2026
Same author

In Reply to Shaffer et al.

Practical radiation oncology·2026
Same author

Saroglitazar 4 Mg in Metabolic Dysfunction-Associated Steatotic Liver Disease: 24-Week Results From Phase 4 Study.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

In Reply to Jordan.

International journal of radiation oncology, biology, physics·2026
Same author

Development and cross-validation of a novel multi-omic assay to assess locoregional recurrence risk and adjuvant therapy benefit in early-stage hormone receptor positive invasive breast cancer patients.

Breast cancer research : BCR·2026

Related Experiment Video

Updated: Jul 25, 2025

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

4.4K

Using Sacubitril/Valsartan to Decrease Health care Costs in Population Health Patients.

Nihanth Damera1, Chirag Shah1, Bistees George1

  • 1Internal Medicine Department, Indiana University School of Medicine, Indianapolis, Indiana.

The American Journal of Cardiology
|June 29, 2023
PubMed
Summary
This summary is machine-generated.

Sacubitril/valsartan significantly reduces health care costs and hospitalizations in heart failure (HF) patients. Utilizing this medication for over 270 days leads to a 22% cost reduction, demonstrating its value in population health management.

More Related Videos

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

459
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.3K

Related Experiment Videos

Last Updated: Jul 25, 2025

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

4.4K
Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

459
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.3K

Area of Science:

  • Health Economics
  • Cardiology
  • Population Health Management

Background:

  • Value-based care models emphasize cost-effectiveness and patient outcomes.
  • The Health care Economic Efficiency Ratio (HEERO) scoring system measures cost benefits in Accountable Care Organizations.
  • Sacubitril/valsartan is recognized for its potential to reduce heart failure (HF) readmissions and healthcare expenditures.

Purpose of the Study:

  • To evaluate the impact of sacubitril/valsartan on HEERO scores and overall healthcare expenditure in HF patients.
  • To compare the cost-effectiveness of sacubitril/valsartan against other standard HF medications.

Main Methods:

  • Patients with HF were enrolled in a population health cohort.
  • HEERO scores were calculated at 3-month intervals for up to one year.
  • Healthcare expenditure and inpatient days were compared across different medication groups, including sacubitril/valsartan, spironolactone, beta-blockers (BB), and ACE inhibitors/ARBs.

Main Results:

  • Sacubitril/valsartan use exceeding 270 days correlated with decreased HEERO scores and inpatient days, indicating reduced healthcare costs (p < 0.0001).
  • A 22% reduction in healthcare costs was observed with 270+ days of sacubitril/valsartan use, primarily due to fewer hospitalizations.
  • In male patients, the combination of sacubitril/valsartan, spironolactone, and BB showed improved HEERO scores and reduced inpatient days compared to standard ACE inhibitor/ARB regimens.

Conclusions:

  • Sacubitril/valsartan use beyond 270 days significantly decreases healthcare expenditure in HF patients within a population health setting.
  • The economic benefits are primarily driven by a reduction in hospitalizations, underscoring sacubitril/valsartan's role in high-value, cost-effective care.
  • Payers should consider subsidizing sacubitril/valsartan to support value-based care and improve patient economic well-being.